13S156: Abstracts: RA – Treatment I: Switching or Discontinuation of Therapies (1585–1590

Abstract Moderator(s)

• 

  Michael Pillinger, MD

  New York University Grossman School of Medicine
  New York,, NY, United States

  Disclosure(s): Fortress: Consultant (Ongoing); Hikma: Grant/Research Support (Ongoing); Horizon: Consultant (Ongoing), Grant/Research Support (Ongoing); Sobi: Consultant (Ongoing)
• YL

  Yvonne Lee, MD, MMSc

  Northwestern University
  Chicago, IL, United States

  Disclosure information not submitted.

Oral abstract session.

Presentations:

• 3:00 PM – 3:10 PM Eastern Time

  Decreased Discontinuation and Switching of B/tsDMARD Therapy in RA Patients When Treatment Is Aligned with a Molecular Signature Response Classifier: An Analysis from the Study to Accelerate Information of Molecular Signatures (AIMS)
  

  Presenting Author: Jeffrey Curtis, MD, MS, MPH – University of Alabama at Birmingham
• 3:10 PM – 3:15 PM Eastern Time

  Q&A
  
• 3:15 PM – 3:25 PM Eastern Time

  Sustained Remission Following the Discontinuation of Tofacitinib in Patients with Rheumatoid Arthritis (XANADU Study): A Multicenter, Prospective, and Randomized Controlled Study
  

  Presenting Author: Satoshi Kubo, MD, PhD – Department of Molecular Targeted Therapies (DMTT), University of Occupational and Environmental Health, Japan
• 3:25 PM – 3:30 PM Eastern Time

  Q&A
  
• 3:30 PM – 3:40 PM Eastern Time

  Efficacy and Safety of Curcumin in Maintaining Remission During Disease Modifying Anti Rheumatic Drug Withdrawal in Rheumatoid Arthritis at 52 Weeks: Phase III Double-Blind Randomized Placebo Controlled Trial
  

  Presenting Author: Sakir Ahmed, DM – Kalinga Institute of Medical Sciences
• 3:40 PM – 3:45 PM Eastern Time

  Q&A
  
• 3:45 PM – 3:55 PM Eastern Time

  Outcomes of Etanercept and Janus Kinase Inhibitor Treatment After First-line Use of Adalimumab in Patients with Rheumatoid Arthritis
  

  Presenting Author: Dimitrios Pappas, MD, MPH – CorEvitas
• 3:55 PM – 4:00 PM Eastern Time

  Q&A
  
• 4:00 PM – 4:10 PM Eastern Time

  Multiple Switching Between the Biosimilar Adalimumab PF-06410293 (Abrilada™) and Reference Adalimumab (Humira®)in Combination with Methotrexate in Patients with Moderately to Severely Active Rheumatoid Arthritis
  

  Presenting Author: Roy Fleischmann, MD – Metroplex Clinical Research Center and University of Texas Southwestern Medical Center
• 4:10 PM – 4:15 PM Eastern Time

  Q&A
  
• 4:15 PM – 4:25 PM Eastern Time

  Pain and Treatment Switching Among Patients in the CorEvitas^TM Rheumatoid Arthritis Registry
  

  Presenting Author: Joshua Baker, MD, MS – University of Pennsylvania
• 4:25 PM – 4:30 PM Eastern Time

  Q&A